Background: The UK Prostate Cancer Risk Management Programme has recommended that all assays for prostate-specific antigen (PSA) should be both equimolar in their response to free and complexed PSA and calibrated to the World Health Organization (WHO) First International Standard for PSA (90:10). To determine which assays currently being used by diagnostic laboratories in England fulfil these criteria, a PSA recovery experiment was performed.
Introduction
Inter-method comparisons for prostate-speci¢c antigen (PSA) are complicated by questions of calibration, equimolarity and assay dynamics. 1 All of these factors can contribute to variability in the PSA results returned on any one patient sample. A Prostate Cancer Risk Management Programme (PCRMP) for England was announced by the Government in 2001, 2 although the associated resource packs were not distributed to the primary care sector until September 2002. One of the main aims of the programme was to ensure that men who are concerned about the risk of prostate cancer could receive information about the advantages and disadvantages of the PSA test, and about the uncertainties associated with the test. The National Screening Committee required equity of access to the programme and equity of quality of service, including analytical quality in the laboratory. The PCRMP needs to be able to recommend a single age-speci¢c level of PSA, 3 above which further investigation is indicated, and to achieve parity of numerical performance in di¡erent geographical areas within the UK. The National Screening Committee, through the Scienti-¢c Reference Group (SRG) of the PCRMP, commissioned a taskforce to review the pre-analytical and post-analytical variables in the measurement of PSA. 4 This taskforce recommended that the most consistent national performance would be achieved by the use of equimolar assays calibrated in relation to the international standard; an equimolar assay being de¢ned as one which measures the two principal forms of PSA (free and complexed PSA 5 ) equally. This recommendation was adopted by the SRG and reiterated by the National Cancer Director in Annex A to his Executive Letter of 23 September 2002. 6 The PSA Calibration and Isoform Working Party of the SRG designed an experiment to demonstrate the traceability of calibration to the WHO First International Standard for PSA (90:10) and the molar responsiveness of commercial assays for PSA currently in use in laboratories in England. The UK National External Quality Assessment Service (UK NEQAS) was commissioned by NHS Cancer Screening on behalf of the SRG of the PCRMP to prepare and distribute the de¢ned samples as an exercise distinct from their routine performance evaluation programme. This paper presents the results of this experiment and proposes a categorization of the assays on the basis of the estimated impact that their bias and non-equimolarity will have on the clinical decision-making process.
Materials and methods
The WHO First International Standard for total PSA (90:10) (NIBSC 96/670) and the WHO First International Standard for free PSA (NIBSC 96/668) were obtained from the National Institute of Biological Standards and Control (NIBSC), Potters Bar, Herts, UK. Four vials of each standard, assigned value 1.0 mg/ampoule, 7 were each reconstituted with 2.0 mL distilled water. The contents of the four vials of NIBSC 96/670 were pooled and further diluted in 4.5% human serum albumin (ZENALBt 4.5, BPL, Elstree, Herts, UK) to give three materials with total PSA concentrations of 2.0, 5.0 and 10.0 mg/L. The four vials of NIBSC 96/668 were reconstituted, pooled and diluted in a similar fashion to give three materials with free PSA concentrations of 2.0, 5.0 and 10.0 mg/L. At each concentration of PSA, the materials derived from NIBSC 96/670 and NIBSC 96/668 were combined in the ratios 100:0, 75:25, 50:50, 25:75, and 0:100. This resulted in 15 samples, ¢ve for each of the PSA concentrations, containing 10%, 32.5%, 55%,77.5% and 100% free PSA.
The 15 samples were coded and sent to all participating laboratories in England with the instruction to assay the samples in a single analytical batch. Results were returned to UK NEQAS with details of analytical platform, including manufacturer's product code and lot number. After removal of laboratory identi¢er information, the results and method details were forwarded to NHS Cancer Screening for statistical evaluation. Analytical platforms were assigned to one of11method codes, as detailed in Table 1 .
Statistical analyses
Each reported PSA result was converted into a recovery percentage as follows:
ðReported PSA À Known PSAÞ=Known PSA Â 100 where known PSAwas either 2,5 or10 mg/L, depending on which sample was been reported.
Molar response plots were prepared for each method and laboratory combination to investigate method consistency between laboratories. In these plots, recovery percentages are plotted against the proportion of freeto-total PSA, with the line of best ¢t estimated by a locally weighted smooth curve. 8 Also plotted is the line corresponding to an unbiased equimolar response method, which is a straight line with zero slope at 100%. Biased methods will systematically report results which are either greater than or less than 100%, while non-equimolar methods correspond to estimated best ¢t lines which have a signi¢cant positive or negative slope across the range of free-tototal PSA percentages.
Means and geometric coe⁄cients of variation were calculated for each method and by each total PSA concentration and free-to-total PSA percentage. The geometric coe⁄cient of variation is the anti-log of the estimate of the standard deviation of the log-transformed trimmed data. The lowest and highest 5% of the results were trimmed to improve the reliability of the estimate.
A linear random intercept model was estimated, with laboratory included as the random intercept term in order to account for di¡erences between laboratories. The relationship between the proportion of freeto-total PSA, and the recovery percentage was assumed to be linear. The ¢tted model is of the form where R is the recovery percentage, B is the unknown parameter corresponding to the amount of bias at 0% free PSA, L i is a random intercept term for the laboratory assumed to be normally distributed with zero mean and a ¢xed variance, E is the unknown parameter corresponding to the amount of non-equimolarity, F is the proportion of free-to-total PSA and Er is a residual error term. Separate models were ¢tted with and without adjustment for total PSA concentration (as a three-factor categorical variable) to see if the recovery percentages varied systematically between total PSA levels. Models were compared by means of a likelihood ratio test. All analyses were performed separately for each method; if a method consisted of more than one product from the same manufacturer (methods 2, 8, 9 and 11), additional analyses were performed to test for di¡erences between manufacturers' products. The estimated bias at three free-to-total PSA combinations re£ecting the situation of a man with prostate cancer (free:total of 10%), a disease-free man (free:total of 30%), and a man with benign prostate hyperplasia (free:total of 50%), were plotted along with 99% con¢dence intervals for each method at a total PSA concentration of 5 mg/L. Additionally, an estimate of the proportion of overall variation that was explained by the inclusion of a random intercept term corresponding to a laboratory was calculated as the ratio of the standard error of the intercept term to the sum of the standard error of the intercept term and the residual standard error.
All statistical analyses were performed in the data analysis and graphics language R. 9
Results
A total of 223 laboratories were sent a complete set of samples for analysis, of which 205 returned results (92% response rate). Initial data screening removed data from ¢ve laboratories which were using a method not in use in any other laboratory, two laboratories who failed to provide details of the PSA assay manufacturer, one laboratory who reported only two possible values for all 15 samples and a further six individual data points were unusable due to transcription errors. The total number of laboratories reporting results for each of the methods is shown in Table 1 . Figure 1 summarizes the data by method and total PSA combination (the molar response plots for each of the methods by laboratory are provided in the Appendix). For each of the methods, there is observable variation between laboratories in terms of the amount of bias reported. For any particular method, however, the overall slope of the best ¢t line appears similar for each laboratory (Appendix). For certain methods, there appears to be systematic di¡erences in the amount of bias associated with the di¡erent levels of total PSA, being most noticeable for method 6 with a bias ranging from approximately 20% at 2 mg/L to 0% at 10 mg/L, when free PSA is10%. Between methods there is considerable variation; methods 2, 4, and 5 have a consistent positive bias of at least 10%, methods 7 and 11 have a small negative bias of no more than10%, methods 2 and 8 are positively skewed with their bias being approximately 18% higher when free PSA is 100% compared with free PSA of 10%, while methods 6 and 10 are negatively skewed with a bias around 15% lower when free PSA is 100% compared with 10%. Table 2 summarizes the overall mean recovery percentages for each method and free-to-total combination, along with their estimated geometric coe⁄cients of variation. Within a method the coe⁄cient of variation is similar for each of the three concentrations of total PSA and across all free-to-total combinations. However, there are di¡erences in the amount of variation between methods, with methods 1, 4 and 6 having the lowest coe⁄cients of variation, at under 4%, and methods 2 and 5 some of the highest, at over 6.5%. Linear mixed-model regression analysis shows that for almost all methods, there is a signi¢cant di¡erence (P-valueso0.001) in the recovery percentages between the three total PSA levels (methods 2, 5, 10 and 11 showed no di¡erences). For methods 2, 8, 9 and 11, which included more than one manufacturers' product, there were no signi¢cant di¡erences in PSA recovery between the products, either in the estimates of bias or of non-equimolarity, and the products therefore can be treated as a single method. All further analyses are, however, adjusted for total PSA level --this implies that there are three estimates of bias for each method, one for each total PSA concentration of 2,5 and10 mg/L. For the remainder of this paper, we will consider only the estimates of bias at 5 mg/L, although data from other concentrations of total PSA will be included in the analysis for the estimation of the non-equimolarity parameter. Table 3 presents the estimates of bias and non-equimolarity from the linear regression analysis and their associated standard errors for each method. No method is both unbiased and equimolar, and there is wide variation between methods. When free PSA is 0%, method 2 has the highest positive bias (23%) while method 7 is the most negatively biased at À5%. Equimolarity ranges from method 2, which has a positive skew estimate of 0.28, to method 6, which has a negative skew of 0.18 --these estimates correspond to the change in percentage bias when the proportion of free PSA increases by1%. The proportion of the overall variation explained by the inclusion of the random intercept corresponding to a laboratory e¡ect is also shown in Table 3 . The higher the percentage variation explained, the more consistent the performance of the method between laboratories; for example methods 5,6 and 8 have a very consistent performance while methods 2 and 7 are most variable. Figure 2 plots the estimated bias for each method when total PSA is 5 mg/L and the percentage of free PSA is 10%, 30% and 50%. These levels of free PSAwere 
Discussion
This study is one of the largest PSA recovery studies which has been systematically designed to assess the bias and equimolarity of commercial assays in use in diagnostic biochemistry laboratories in England. It has shown clear di¡erences between methods, such that they can be both biased and/or non-equimolar and that no method is truly unbiased and equimolar in its response to free and complexed PSA. Assays for the measurement of PSA have considerable di¡erences in their epitope recognition which can result in signi¢cantly di¡erent values of PSA for the same serum sample. 10, 11 Historically, bias in PSA assays originated from the use of di¡erent 'primary'standards with variation in the estimation of their mass equivalence. Previous inter-method di¡erences of between two-and ¢ve-fold were seen in patients with di¡ering proportions of free PSA; di¡erences in basic calibration being compounded by di¡erences in molar responsiveness of the various assay kits. 12--14 The introduction of the Stanford University calibrators 15 and the National Committee for Clinical Laboratory Standards (NCCLS) guidelines 16 and their rapid adoption by industry eliminated the more extreme cases of assay bias, but signi¢cant inter-method variability has persisted. This relates, in the main, to the method of data transfer between the primary standards and the 'master calibrator', and between the master calibrator and the individual kit calibrators. Depending on the composition of the kit calibrators, the molar responsiveness of the assay, itself a combination of antibody speci¢city and a⁄nity and assay kinetics, 17 will also contribute to the assay bias relative to the selected primary standard. When using a universal action limit along with methods from a wide range of manufacturers, as is the Free:total 10% (prostate cancer) Free:total 30% (disease free) Free:total 50% (BPH) Figure 2 Estimated method bias (and 99% confidence intervals) from a linear random intercept model when PSA is 5 mg/L at three free:total PSA ratios corresponding to a man with prostate cancer (free PSA of 10%), a disease-free man (free PSA of 30%), and a man with benign prostate hyperplasia (free PSA of 50%). The horizontal dashed line corresponds to the expected results from a calibrated and equimolar method, while the two horizontal dotted lines represent the proposed limits of acceptability for bias of 10% case in the UK Prostate Cancer Risk Management Programme, 3 it is critical for the equality of the testing procedure that all methods should be calibrated to the international standard. However, the controversy regarding the clinical relevance of equimolar responsiveness remains; 18 recently, the clinical impact of non-equimolarity has been studied by means of a computer simulation experiment. 19 This paper showed that if a method with a positive bias or equivalently a positive skew is used to determine PSA, then men could be judged to be test positive (over a action limit) even though their true (simulated) PSA level was under the limit. Similarly men could be test-negative when their true PSAwas test-positive if a negatively biased or negatively skewed method was used. These false-positives and false-negatives have major clinical implications for those men being tested; false-positives su¡er greater psychological stress and are required to undergo an invasive clinical procedure for diagnostic con¢rmation, while the false-negatives are given wrongful assurances that they are free of cancer. While it is reasonable to expect a degree of bias and non-equimolarity in any immunoassay, acceptable performance limits (on bias and equimolarity) need to be set to ensure that no one method can have a detrimental impact on clinical outcomes. Rather than using arbitrary limits without reference to the clinical decision making process, an alternative is to utilize the approach of Roddam et al. 19 and determine, for a range of realistic scenarios, the clinical impact of bias and non-equimolarity in terms of false-positive and falsenegative rates. On the basis of this report, methods should be no more than 10% biased for each of the free PSA levels seen in clinical practice (i.e. between 10% and 50%), since this would correspond to an overall false recommendation rate (false-positives plus falsenegatives) of 2.5% ( 19 for an equimolar method). It should be noted that it is only at PSA levels close to the cut-o¡ point where bias and non-equimolarity have the greatest impact; hence the current manuscript has focused speci¢cally on estimates of bias at 5 mg/L for a range of plausible free PSA percentages. On the basis of these estimates we can assign each method to one of three groups: (A) those with unacceptable characteristics, (B) those with borderline characteristics, and (C) those with acceptable characteristics, corresponding to whether the estimated biases displayed in Figure 2 were (A) greater than 10% (B) some greater and some less than 10% or (C) less than10%. This proposed grouping results in the following categorization: (A) methods 2, 4 and 5, (B) methods 9 and 10, and (C) methods 1, 3, 6,7, 8 and 11.
A number of authors have studied the clinical performance of assays that have been recalibrated, 20, 21 with some noting improvements in performance characteristics normally assessed by sensitivity and speci¢city.
However, as most of these studies have been performed prior to the development of the international standards, it is impossible to assess whether the recalibration has actually changed the assays' performance characteristics in terms of bias or equimolarity. The advent of the international standards and the current study means that in future if manufacturers re-calibrate their assays, or if new assays for PSA are developed, it will be possible to assess their performance characteristics in a transparent manner which does not rely on clinical samples. Further, using the data from this study it is possible to develop a simpler version of the experiment that can be used both as a test for a new assay and as part of an ongoing monitoring programme to detect changes in assay performance over time.
A major strength of this study is that it has been carried out in the operating environment in which these assays are being used, and the participating laboratories were blinded as to the concentrations and compositions of the 15 specimens they received. The samples were all prepared and distributed according to a standardized handling protocol by a small number of individuals, enhancing the comparability of the distributed material; only di¡erences in the handling process post preparation, by the individual laboratories, could a¡ect the results. As demonstrated there is a degree of inter-laboratory variation within each of the methods; however, the overall estimates of bias and non-equimolarity accounted for these di¡erences. A potential problem with the current study is that some of the samples distributed contained proportions of free PSA far in excess of the levels normally seen in clinical practice. 22 However, the analyses showed rather consistent performance characteristics over the whole free PSA range, suggesting that method performance does not deteriorate at high levels of free PSA. Moreover the operating ranges of the methods tested in this experiment cover the three concentrations of total PSA distributed.
In summary, this large-scale recovery study has shown that methods currently in use for PSA have varying degrees of bias and non-equimolarity which can have a signi¢cant impact on the clinical decisionmaking process. It is essential that methods for PSA are equimolar in their response to free and complexed PSA and calibrated to the International Standards to minimise the likelihood of clinical errors due to calibration issues. 
